tbuckley/cabot-search huggingface dataset:
YIA23-005: Early Interim Analysis of a Phase II Randomized Trial of Moderate Versus Ultra-Hypofractionated Post-Prostatectomy Radiation Therapy
Authors: William C. Jackson, Krithika Suresh, Daniel E. Spratt, Robert T. Dess
Journal: Journal of the National Comprehensive Cancer Network (2023)

"YIA23-005: Early Interim Analysis of a Phase II Randomized Trial of Moderate Versus Ultra-Hypofractionated Post-Prostatectomy Radiation Therapy" published on 31 Mar 2023 by National Comprehensive Cancer Network.
BIO23-017: Patient Satisfaction With Electronic Health Records: Results From a Survey of Morrocan Patients in Mohammed VI Oncology Center
Authors: Sara Mounaime, Maryam Zaouit, Mouna Bourhafour, Tarek Chekrine, Zineb Bouchbika, Nadia Benchakroun, Hassan Jouhadi, Souha Sahraoui, Abdellatif Benider, Nezha Tawfiq
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BIO23-017: Patient Satisfaction With Electronic Health Records: Results From a Survey of Morrocan Patients in Mohammed VI Oncology Center" published on 31 Mar 2023 by National Comprehensive Cancer Network.
QIM23-148: Effectiveness of a Provider Education Intervention for Increasing Human Papillomavirus Vaccine Uptake at Pediatric Clinics Within a Safety-Net Health System
Authors: Rachel Meadows, Yan Lu, Grace Maynard, Idara N. Akpan, Aaron W. Gehr, Tanjila Taskin, Kimberly Fulda, Divya Patel, Rohit P. Ojha, Erika L. Thompson
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-148: Effectiveness of a Provider Education Intervention for Increasing Human Papillomavirus Vaccine Uptake at Pediatric Clinics Within a Safety-Net Health System" published on 31 Mar 2023 by National Comprehensive Cancer Network.
BIO23-020: A Novel Semi-Supervised Learning Algorithm for Prognosis-Oriented Classification and Biomarker Identification of Colorectal Cancer
Authors: Liyi Bai, Fanqin Bu, Xiangji Li, Xiaohan Yang, Shutian Zhang, Li Min
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BIO23-020: A Novel Semi-Supervised Learning Algorithm for Prognosis-Oriented Classification and Biomarker Identification of Colorectal Cancer" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Rational engineering of glycosaminoglycan-based Dickkopf-1 scavengers to improve bone regeneration
Authors: Gloria Ruiz-Gómez, Juliane Salbach-Hirsch, Jan-Niklas Dürig, Linda Köhler, Kanagasabai Balamurugan, Sandra Rother, Sophie-Luise Heidig, Stephanie Moeller, Matthias Schnabelrauch, Giulia Furesi, Sophie Pählig, Pedro M. Guillem-Gloria, Christine Hofbauer, Vera Hintze, M. Teresa Pisabarro, Jörg Rademann, Lorenz C. Hofbauer
Journal: Biomaterials (2023)
QIM23-136: Nurse Navigators Charted a Course for Equitable Care in Multiple Myeloma: Simplifying QI to Measure the Impact of Accredited Education
Authors: Lilia Zurkovsky, Amy Pierre, Natasha Mitchner, Vanessa Senatore, Christine Hofmeyer
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-136: Nurse Navigators Charted a Course for Equitable Care in Multiple Myeloma: Simplifying QI to Measure the Impact of Accredited Education" published on 31 Mar 2023 by National Comprehensive Cancer Network.
BIO23-022: Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center’s Tobacco Treatment Offerings: An Acceptability Pilot Study
Authors: Riley Walton Jackson, Ann Cao-Nasalga, Amy Chieng, Amy Pirkl, Annemarie D. Jagielo, Cindy Tran, Emilio Goldenhersch, Nicolas Rosencovich, Cristian Waitman, Judith J. Prochaska
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BIO23-022: Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center’s Tobacco Treatment Offerings: An Acceptability Pilot Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
EPR23-077: Incidence and Mechanisms of Coexisting Hematological Malignancies: Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia—A Retrospective Review
Authors: Sujan Badal, Mariam Alamgir
Journal: Journal of the National Comprehensive Cancer Network (2023)

"EPR23-077: Incidence and Mechanisms of Coexisting Hematological Malignancies: Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia—A Retrospective Review" published on 31 Mar 2023 by National Comprehensive Cancer Network.
BPI23-010: The Benefits of a Clinically Based Individualized Exercise Oncology Program on Health Care Utilization in Patients With Malignancies
Authors: Karen Wonders, Jay K Harness, Arthur G Lerner
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BPI23-010: The Benefits of a Clinically Based Individualized Exercise Oncology Program on Health Care Utilization in Patients With Malignancies" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Author correction to ‘Discovery of the radio-protecting effect of ecliptae herba, its constituents and targeting p53-mediated apoptosis in vitro and in vivo’ [Acta Pharm Sin B 13 (2023) 1216–1230]
Authors: Jiang Wu, Wenfeng Gou, Zhiyun Wang, Huajie Chang, Deguan Li, Wenbin Hou, Changxiao Liu
Journal: Acta Pharmaceutica Sinica B (2023)

[This corrects the article DOI: 10.1016/j.apsb.2022.09.003.].
CLO23-033: Why Did 560 Azerbaijan Population Women Have De Novo Stage IV Breast Cancer?
Authors: Elchin B. Mansurov, Jamil A. Aliyev, Sevinj E. Rahimzade, Leylakhanum A. Melikova, Konul S. Mardanova, Turkan E. Mansurova
Journal: Journal of the National Comprehensive Cancer Network (2023)
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
Authors: Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Löfgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandéus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Øyvind Salvesen, Asgeir Store Jakola
Journal: JAMA Network Open (2023)

Importance Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. One of the proposed indications is for the treatment of glioblastoma. Objective To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma. Design, Setting, and Participants This was a multicenter, open-label, randomized phase II/III clinical trial with parallel group design. Patients were recruited at 7 study sites in Sweden and 2 sites in Norway between January 2017 and November 2020. Eligible patients were 18 years or older, had a first recurrence of glioblastoma, and indication for treatment with alkylating chemotherapy. Patients were followed up until death or a maximum of 24 months. The date of final follow-up was January 15, 2021. Data analysis was performed from February to September 2022. Interventions Patients were randomized 1:1 to receive either standard-of-care (SOC) alkylating chemotherapy alone, or SOC with the addition of disulfiram (400 mg daily) and copper (2.5 mg daily). Main Outcomes and Measures The primary end point was survival at 6 months. Secondary end points included overall survival, progression-free survival, adverse events, and patient-reported quality of life. Results Among the 88 patients randomized to either SOC (n = 45) or SOC plus disulfiram and copper (n = 43), 63 (72%) were male; the mean (SD) age was 55.4 (11.5) years. There was no significant difference between the study groups (SOC vs SOC plus disulfiram and copper) in 6 months survival (62% [26 of 42] vs 44% [19 of 43]; P = .10). Median overall survival was 8.2 months (95% CI, 5.4-10.2 months) with SOC and 5.5 months (95% CI, 3.9-9.3 months) with SOC plus disulfiram and copper, and median progression-free survival was 2.6 months (95% CI, 2.4-4.6 months) vs 2.3 months (95% CI, 1.7-2.6 months), respectively. More patients in the SOC plus disulfiram and copper group had adverse events grade 3 or higher (34% [14 of 41] vs 11% [5 of 44]; P = .02) and serious adverse events (41% [17 of 41] vs 16% [7 of 44]; P = .02), and 10 patients (24%) discontinued disulfiram treatment because of adverse effects. Conclusions and Relevance This randomized clinical trial found that among patients with recurrent glioblastoma, the addition of disulfiram and copper to chemotherapy, compared with chemotherapy alone, resulted in significantly increased toxic effects, but no significant difference in survival. These findings suggest that disulfiram and copper is without benefit in patients with recurrent glioblastoma. Trial Registration ClinicalTrials.gov Identifier: NCT02678975 ; EUDRACT Identifier: 2016-000167-16
CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data
Authors: Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, Luis Souhami
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data" published on 31 Mar 2023 by National Comprehensive Cancer Network.
EPR23-078: Analyzing Trends in the Incidence and Mortality of Esophageal Cancer in the United States: A 15-Year Population-Based Study
Authors: Neethi Dasu, Kirti Dasu, Jason John, Yaser Khalid, Brian Blair, Lucy Joo, C. Jonathan Foster
Journal: Journal of the National Comprehensive Cancer Network (2023)

"EPR23-078: Analyzing Trends in the Incidence and Mortality of Esophageal Cancer in the United States: A 15-Year Population-Based Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-064: PD-1/PD-L1 Inhibitors in Advanced and Metastatic Esophageal Carcinoma: An Updated Meta-Analysis of Randomized Controlled Trials
Authors: Akshit Chitkara, Femina Patel, Rushin Patel, FNU Anamika, Rajat Thawani
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-064: PD-1/PD-L1 Inhibitors in Advanced and Metastatic Esophageal Carcinoma: An Updated Meta-Analysis of Randomized Controlled Trials" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CGE23-075: Tumor Transcriptomic Profile in Patients (pts) With Synchronous Versus Metachronous Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Authors: Haoran Li, Jong Taek Kim, Beverly Chigarira, Kamal Kant Sahu, Georges Gebrael, Shruti Adidam Kumar, Nishita Tripathi, Nicolas Sayegh, Vinay Matthew Thomas, Umang Swami, Neeraj Agarwal, Benjamin L. Maughan
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CGE23-075: Tumor Transcriptomic Profile in Patients (pts) With Synchronous Versus Metachronous Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-051: Real-World Use of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer Following Prior Ado-Trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade With Pertuzumab Plus Trastuzumab
Authors: Kelly E. McCann, Nina Oestreicher, Christopher G. Rowan, Gregory A. Vidal
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-051: Real-World Use of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer Following Prior Ado-Trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade With Pertuzumab Plus Trastuzumab" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information
Authors: Ali Tafazzoli, Alissa Shaul, Weicheng Ye, Anuraag R. Kansal, A. Mark Fendrick
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting
Authors: Dariusz Uczkowski, Arunabh Sekhri, Shilpi Gupta, Leah Gendler, Krzysztof Misiukiewicz, Miles Levin, Bonni Guerin
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity
Authors: Maria Philip, Jomon Raphael Chalissery, Febin Antony, Rajkrishna B, Mathew Varghese K
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-106: Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study
Authors: Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, Ching-Kun Wang
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-106: Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
QIM23-133: Aligning NCCN Criteria With Testing Workflows Using a Novel Database Application (Criterion™)
Authors: Jivesh Sharma, Rena J. Vanzo, Tawanna St. Lewis, Cheryl Reeves, Pranav Mukund, Neal Sharma, Morgan Tolley, John Tan, Poonam Sharma, Rekha Sharma
Journal: Journal of the National Comprehensive Cancer Network (2023)
Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood‒brain barrier
Authors: Thuy Giang Nguyen Cao, Ji Hee Kang, Su Jin Kang, Quan Truong Hoang, Han Chang Kang, Won Jong Rhee, Yu Shrike Zhang, Young Tag Ko, Min Suk Shim
Journal: Acta Pharmaceutica Sinica B (2023)

Glioblastoma (GBM) is the most aggressive malignant brain tumor and has a high mortality rate. Photodynamic therapy (PDT) has emerged as a promising approach for the treatment of malignant brain tumors. However, the use of PDT for the treatment of GBM has been limited by its low blood‒brain barrier (BBB) permeability and lack of cancer-targeting ability. Herein, brain endothelial cell-derived extracellular vesicles (bEVs) were used as a biocompatible nanoplatform to transport photosensitizers into brain tumors across the BBB. To enhance PDT efficacy, the photosensitizer chlorin e6 (Ce6) was linked to mitochondria-targeting triphenylphosphonium (TPP) and entrapped into bEVs. TPP-conjugated Ce6 (TPP-Ce6) selectively accumulated in the mitochondria, which rendered brain tumor cells more susceptible to reactive oxygen species-induced apoptosis under light irradiation. Moreover, the encapsulation of TPP-Ce6 into bEVs markedly improved the aqueous stability and cellular internalization of TPP-Ce6, leading to significantly enhanced PDT efficacy in U87MG GBM cells. An in vivo biodistribution study using orthotopic GBM-xenografted mice showed that bEVs containing TPP-Ce6 [bEV(TPP-Ce6)] substantially accumulated in brain tumors after BBB penetration via transferrin receptor-mediated transcytosis. As such, bEV(TPP-Ce6)-mediated PDT considerably inhibited the growth of GBM without causing adverse systemic toxicity, suggesting that mitochondria are an effective target for photodynamic GBM therapy.
HSR23-123: Conventional Hydration Versus Short Hydration for Reducing Chemotherapy Induced Nephrotoxicity (CIN) Among Adult Esophageal Cancer Patients at Uganda Cancer Institute, Mbarara – Uganda: An Interventional Study
Authors: John Isiiko, Idrine Kato, Imelda Busingye, Semei Sekitene
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-123: Conventional Hydration Versus Short Hydration for Reducing Chemotherapy Induced Nephrotoxicity (CIN) Among Adult Esophageal Cancer Patients at Uganda Cancer Institute, Mbarara – Uganda: An Interventional Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Celastrol suppresses humoral immune responses and autoimmunity by targeting the COMMD3/8 complex
Authors: Taiichiro Shirai, Akiko Nakai, Emiko Ando, Jun Fujimoto, Sarah Leach, Takao Arimori, Daisuke Higo, Floris J. van Eerden, Janyerkye Tulyeu, Yu-Chen Liu, Daisuke Okuzaki, Masanori A. Murayama, Haruhiko Miyata, Kazuto Nunomura, Bangzhong Lin, Akiyoshi Tani, Atsushi Kumanogoh, Masahito Ikawa, James B. Wing, Daron M. Standley, Junichi Takagi, Kazuhiro Suzuki
Journal: Science Immunology (2023)

Celastrol, a bioactive molecule extracted from the Tripterygium wilfordii plant, has been shown to exhibit anti-inflammatory properties. However, its mechanism of action has not been fully elucidated. Here, we show that celastrol suppresses humoral immune responses and autoimmunity by disabling a protein complex consisting of copper metabolism MURR1 domain–containing (COMMD) 3 and COMMD8 (COMMD3/8 complex), a signaling adaptor for chemoattractant receptors. Having demonstrated the involvement of the COMMD3/8 complex in a mouse model of rheumatoid arthritis, we identified celastrol as a compound that covalently bound to and dissociated the COMMD3/8 complex. Celastrol inhibited B cell migration, reduced antibody responses, and blocked arthritis progression, recapitulating deficiency of the COMMD3/8 complex. These effects of celastrol were abolished in mice expressing a celastrol-resistant mutant of the COMMD3/8 complex. These findings establish that celastrol exerts immunosuppressive activity by targeting the COMMD3/8 complex. Our study suggests that the COMMD3/8 complex is a potentially druggable target in autoimmune diseases and points to celastrol as a lead pharmacologic candidate in this capacity.
HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti–PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature
Authors: Daniel Olson, Brian Gastman, Alicia Rowell, Madan Jagasia, Parameswaran Hari, Wen Shi, Kendall Stevinson, Katy K. Tsai
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti–PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-109: Real-World Combination Use of Mogamulizumab With Other Therapies Among Patients With Mycosis Fungoides and Sézary Syndrome
Authors: Yang Zhao, Jackson Tang, Chunlan Chang, Zhishui Zheng, Takeshi Takahashi, Takanobu Nomura, Robert Ristuccia, Eslie Dennis
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-109: Real-World Combination Use of Mogamulizumab With Other Therapies Among Patients With Mycosis Fungoides and Sézary Syndrome" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Authors: Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey Weber, Laura C Cappelli
Journal: Journal for ImmunoTherapy of Cancer (2023)

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guidelines for irAE management can be challenging for practitioners due to a lack of common or consistently applied terminology. Furthermore, given the growing body of clinical experience and published data on irAEs, there is a greater appreciation for the heterogeneous natural histories, responses to treatment, and patterns of these toxicities, which is not currently reflected in irAE guidelines. Furthermore, there are no prospective trial data to inform the management of the distinct presentations of irAEs. Recognizing a need for uniform terminology for the natural history, response to treatment, and patterns of irAEs, the Society for Immunotherapy of Cancer (SITC) convened a consensus panel composed of leading international experts from academic medicine, industry, and regulatory agencies. Using a modified Delphi consensus process, the expert panel developed clinical definitions for irAE terminology used in the literature, encompassing terms related to irAE natural history (ie, re-emergent, chronic active, chronic inactive, delayed/late onset), response to treatment (ie, steroid unresponsive, steroid dependent), and patterns (ie, multisystem irAEs). SITC developed these definitions to support the adoption of a standardized vocabulary for irAEs, which will have implications for the uniform application of irAE clinical practice guidelines and to enable future irAE clinical trials.
HSR23-105: Real-World Dosing Patterns in Patients With Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Treated With Brigatinib in the Front-Line (FL) Setting in the United States: A Claims Database Analysis
Authors: Edmund W. Tai, Huamao Mark Lin, Yanyu Wu, Yin Wan, Magdaliz Gorritz, Xiaoyu Zhou, Chi-Chang Chen, Yuanbin Chen
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-105: Real-World Dosing Patterns in Patients With Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Treated With Brigatinib in the Front-Line (FL) Setting in the United States: A Claims Database Analysis" published on 31 Mar 2023 by National Comprehensive Cancer Network.
QIM23-141: An APP Initiated Telehealth Visit to Reduce Oncology Patient Readmissions: Lessons Learned
Authors: Sarah McCaffrey, Crystal Wolf, Paula Goldberg, Margaret Faul, Emily Pagel, Alexandria Westerman, Anna McComas, Bindiya G. Patel, Patricia Litkowski, Olivia Aranha
Journal: Journal of the National Comprehensive Cancer Network (2023)
QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study
Authors: Amye J. Tevaarwerk, Elizabeth S. Harlos, Matthew J. Maurer, Heather L. VanBebber, Eli J. Misel, Sacha A. Nelson, Sara J. Holton, Abigail L. Stockham, Tufia C. Haddad, Steven R. Alberts, Robert R. McWilliams, Sumithra J. Mandrekar
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
BPI23-013: Comparison of Modified Patient-Reported Paper G8 and EPIC G4 + 4 With Clinician-Reported Standard G8 to Screen Frailty in Elderly Patients With Cancer
Authors: Jessica Zhu, Diana Abbott, Corbin Eule, Maksym Goryachok, Theresa Tafoya, Sarah Roberts, Andrea Nederveld, Hillary Lum, Daniel Sherbenou, Elizabeth R. Kessler
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BPI23-013: Comparison of Modified Patient-Reported Paper G8 and EPIC G4 + 4 With Clinician-Reported Standard G8 to Screen Frailty in Elderly Patients With Cancer" published on 31 Mar 2023 by National Comprehensive Cancer Network.